USA-based cancer therapy discoverer Tango Therapeutics has entered into a global strategic collaboration to discover, develop and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer which could earn the venture capital-backed firm $1.75 billion.
Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead Sciences (Nasdaq: GILD) will have options to worldwide rights on up to five targets emerging from Tango's proprietary functional genomics-based discovery platform. For two programs directed to these targets, Tango will retain the option to co-develop and co-detail in the USA. The collaboration does not include Tango's lead programs, for which Tango will retain all rights.
Gilead’s shares were down 5.21% at $68.29 as mid-day approached in New York, indicating that investors were not overwhelmed by the news.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze